SLC5A2 and hydrops fetalis: Trials met their endpoints largely through a reduction in HF hospitalizations,8,9 and produced similar results when LVEF was between 25% and 65%.46 The positive effects of empagliflozin were attenuated when LVEF was >65%, unlike dapagliflozin where reduction in the primary endpoint persisted across the spectrum of LVEF.46,47 Nevertheless, a pooled data meta-analysis later identified significant reduction in HF hospitalizations and cardiovascular death for SGLT2 inhibitors across the LVEF spectrum.48